Forecast: Bipolar Disorder.
Datamonitor Healthcare’s latest research uses a patient-based approach to measure the commercial potential of bipolar disorder across the US, Japan, and five major EU markets* from 2014 to 2023. Bipolar disorder sales are forecast to decline from $2.2bn to $1.9bn over the 2014–23 forecast period, at a compound annual growth rate of -1.8%.
With market dynamics set to change, it is vital to understand how these changes will shake up the entire market along with the drivers and resistors to market growth.
Our 10-year sales forecast provides you with in-depth analysis of the market and it’s key brands, helping you to determine competitiveness in the market place. Our sample extract highlights:
- Why long-acting injectable antipsychotics are set to become a key driver of growth
- Bipolar disorder market sales figures ($)
- Forecast assumptions of Seroquel/Seroquel XR (quetiapine; AstraZeneca/Astellas) for the treatment of bipolar disorder
- Seroquel/Seroquel XR sales for bipolar disorder ($)
Explore our forecast on bipolar disorder by downloading your exclusive extract from this market leading report >>
If you’re already a subscriber to Datamonitor Healthcare, click here to access the full report.